**1. iShares Nasdaq Biotechnology ETF (ticker: IBB)**
iShares Nasdaq Biotechnology ETF (IBB) is a life science ETF provided by BlackRock Fund Advisors, and it secures the number one spot on our list. Maintaining a strong portfolio with a heavy emphasis on large-cap biotechnology companies, IBB has continued to deliver commendable returns until 2024. What makes IBB notable is its sound investment in key players of the biotechnology industry such as Moderna, Gilead Sciences, and Amgen. A considerable proportion of the funds are allocated in the U.S., and the assets are cap-weighted with a focus on industry leaders. With an average annual return of 16% over the past 10 years and more than $9 billion in asset base, IBB is the premier choice for investors seeking exposure in the life science sector in 2024.
**2. ARK Genomic Revolution ETF (ticker: ARKG)**
The ARK Genomic Revolution ETF (ARKG) is an actively managed fund centred around companies that are involved in areas such as CRISPR, targeted therapeutics, bioinformatics, molecular diagnostics, and agricultural biology. In spite of being a newer player in the market with its inception in 2014, ARKG has exhibited phenomenal growth. It boasts a portfolio of 30 to 50 companies focused on advancing and benefiting from innovations in genomics. An interesting characteristic of this ETF is its active management strategy, which allows for higher flexibility in response to the rapidly changing landscape of the genomics industry. In 2024, ARKG remains an attractive choice with its enticing promise of high growth potential.
**3. Health Care Select Sector SPDR Fund (ticker: XLV)**
The Health Care Select Sector SPDR Fund (XLV) is an ideal choice for investors who prefer a broader exposure to the healthcare sector, including biotechnology, pharmaceuticals, and healthcare providers and services. XLV invests in stocks from the Health Care Select Sector Index and the S&P 500 index. Some of its top holdings include renowned names such as Johnson & Johnson, Pfizer, and UnitedHealth Group. Its tailored approach enables the fund to offer excellent diversification and risk spread, thereby contributing to its steady performance over the years. With an AUM of over $25 billion, XLV continues to be liked for its continuous strong performance in the healthcare sector.
**4. VanEck
